Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 58

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 58
---
 or deny approval of our product candidates for any or all targeted indications.
Any data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that
the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials.
Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result
in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating
medical staff, as toxicities resulting from T cell therapy are not normally encountered in the general patient population and by medical
personnel. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient
deaths. Any of these occurrences may harm our business, financial condition and prospects significantly.

Our product candidates may target healthy cells expressing target antigens, leading to potentially fatal adverse effects.

Our product candidates target
specific antigens that are also expressed on healthy cells. For example, cell surface phosphatidylserine, the target of CER-1236, has
been observed on activated immune cells, including platelets, and in rapidly dividing cells across various organs including the gastrointestinal
system, hepatic system, cardiovascular system, renal system, pulmonary system, and the central nervous system and related peripheral
nervous system. Our product candidates may target healthy cells, leading to serious and potentially fatal adverse effects. Even though
we intend to closely monitor the side effects of our product candidates in both preclinical studies and clinical trials, we cannot guarantee
that products will not target and kill healthy cells.

<div align='center'>27</div>

Our product candidates may have serious and potentially fatal cross-reactivity to lipids, peptides or protein sequences within the body.

Our product candidates may
recognize and bind to a peptide unrelated to the target antigen to which it is designed to bind. If this peptide is expressed within
normal tissues, our product candidates may target and kill the normal tissue in a patient, leading to serious and potentially fatal adverse
effects. Additionally, our product candidates may bind with non-targeted lipids, leading to off-target reactivity. Detection of any on-target
off-tumor or non-specific-reactivity may halt or delay any ongoing clinical trials for any CER-T cell based product candidate and prevent
or delay regulatory approval. Unknown binding-reactivity of the CER-T cell binding domain to related proteins could also occur. Any non-specific